A Case of Hodgkin Lymphoma Developed in an Ataxia-telangiectasia Patient
10.15264/cpho.2016.23.2.184
- Author:
Ju Yeon LIM
1
;
Mina JEON
;
Hyo Sun KIM
;
Jung Woo HAN
;
Chuhl Joo LYU
;
Seung Min HAHN
Author Information
1. Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea. bluenile88@yuhs.ac
- Publication Type:Case Report
- Keywords:
Ataxia-telangiectasia;
Hodgkin lymphoma;
Chemotherapy;
Brentuximab
- MeSH:
Ataxia;
Ataxia Telangiectasia;
Cerebellar Ataxia;
Child;
Clinical Protocols;
Drug Therapy;
Female;
Hodgkin Disease;
Humans;
Necrosis;
Radiation Tolerance;
Radiotherapy;
Salvage Therapy;
Telangiectasis
- From:Clinical Pediatric Hematology-Oncology
2016;23(2):184-187
- CountryRepublic of Korea
- Language:English
-
Abstract:
Ataxia-telangiectasia (AT) is characterized by cerebellar ataxia, progressive immunodeficiency, radiation sensitivity, telangiectasia, and predisposition to malignancy. AT patients have a 100-fold increased risk for the development of lymphoid malignancies. It is important to consider AT in a child with pre-existing ataxia, or lymphoid malignancy that was diagnosed at a younger age than expected. This consideration avoids the confusion between ataxia development and toxicity from chemotherapy. Hodgkin's lymphoma (HL) is usually treated with chemotherapy and/or radiotherapy. Unfortunately, when treated with conventional doses of radiotherapy, AT patients invariably experience devastating necrosis of their normal tissues. Therefore, a new treatment protocol for patients with HL in AT must be established. In this paper, we report the case of an 8-year-old female patient with HL in AT who was treated with chemotherapy. This patient was also treated with brentuximab (which targets CD30) for salvage therapy after the disease progressed.
